Last reviewed · How we verify
Bmab1200
Bmab1200 is a monoclonal antibody targeting a specific immune or disease-related antigen to modulate immune response or block pathogenic signaling.
At a glance
| Generic name | Bmab1200 |
|---|---|
| Sponsor | Biocon Biologics UK Ltd |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
As a monoclonal antibody in phase 3 development by Biocon Biologics, Bmab1200 is designed to bind to its molecular target with high specificity. The exact mechanism remains proprietary, but the antibody format suggests it functions through immune modulation, receptor blockade, or antigen neutralization. Further clinical data from phase 3 trials will clarify its precise therapeutic mechanism.
Approved indications
Common side effects
Key clinical trials
- Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS). (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |